All Oncology News

Glofitamab plus GemOx received approval in Canada for patients with relapsed or refractory DLBCL not otherwise specified who are not eligible for ASCT.

Joyce O'Shaughnessy, MD, discusses the utility of genomic testing in HR+, HER2– early breast cancer.

The BRF14 study, which examined imatinib in patients with gastrointestinal stromal tumors, has the longest follow-up time in this sarcoma.

Naseema Gangat, MBBS, details updates, novel strategies, and factors that inform decision-making in clinical for patients with hematologic malignancies.

Alberto Martini, MD discusses how systemic treatment approaches and key trials have refined care for patients with BCG-unresponsive NMIBC.

Matthew R. Smith, MD, PhD, discusses how PARP inhibition and radioligand therapies are shaping treatment decisions in advanced prostate cancer.

Three experts discuss the implications of the FDA's removal of REMS requirements for CAR T-cell therapy in hematologic malignancies in the following video.

Alice T. Shaw, MD, PhD, has been named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute.

The European approval of a zanubrutinb tablet formulation covers indications in CLL, Waldenström macroglobulinemia, MZL, and follicular lymphoma.

Alpha1H met all primary and secondary end points in a phase 2 study in non–muscle-invasive bladder cancer.

Five experts gathered for the OncLive Peer Exchange to discuss SCLC data that continues to drive the evolving treatment paradigm.

Clinicians spanning a spectrum of cancer subtypes discuss how they are currently using artificial intelligence in their daily practice.

Naseema Gangat, MBBS, delves into the role of ruxolitinib as a standard of care for the treatment of patients with polycythemia vera and myelofibrosis.

John Marshall, MD, discusses fruquintinib’s efficacy in later-line CRC, advocating for the agent’s use as maintenance therapy to avoid overtreatment.

Matthew R. Smith, MD, PhD, discusses findings from the ARANOTE trial that confirm the efficacy of darolutamide plus ADT in mCSPC.

Huntsman Cancer Institute has announced leadership team appointments overseeing clinical and research efforts in theranostics.

The FDA has approved the MMR IHC Panel pharmDx to determine eligibility for nivolumab/ipilimumab in patients with MSI-H/dMMR colorectal cancer.

Nivolumab plus ipilimumab earned approval from Health Canada for select patients with unresectable colorectal cancer and hepatocellular carcinoma.

The FDA has received a premarket approval application supported by positive results from the PANOVA-3 trial for Tumor Treating Fields (TTFields)—electric fields that exert physical forces to kill cancer cells via a variety of mechanisms—for locally advanced pancreatic cancer.

Maurie Markman, MD, discusses the need to reevaluate how adverse effects are measured and reported with antineoplastic therapies in oncology.

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.

Thomas Powles, MD, MBBS, MRCP, discusses challenges in identifying a predictive biomarker of response for sasanlimab in high-risk, BCG-naive NMIBC.

The FDA issued a complete response letter for subcutaneous daratumumab plus VRd in transplant-ineligible, newly diagnosed myeloma.

Ribociclib plus trastuzumab and an AI produced a median PFS of 30.4 months in patients with hormone receptor–positive, HER2-positive breast cancer.

Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts.

The NCCN guidelines for NSCLC were updated to include zongertinib as a preferred subsequent therapy option for advanced or metastatic HER2-mutant NSCLC.

Magrolimab plus nivolumab and FOLFOX with bevacizumab or cetuximab yielded responses in advanced/recurrent colorectal cancer.

The NMPA has granted breakthrough therapy designation to ATG-022 for previously treated gastric and gastroesophageal junction adenocarcinoma.

Jill Gilbert, MD discusses how being coachable and using feedback effectively can drive personal growth, team success, and continuous professional improvement.

Anlotinib plus epirubicin conferred a significant PFS benefit vs epirubicin monotherapy in advanced soft tissue sarcoma.